

| Equities >3% at 31 January 2018 | (%) |
|------------------------------------|------|
| Lloyds Banking Group | 11.2 |
| Tesco | 10.2 |
| Bellway | 9.4 |
| Sports Direct | 8.6 |
| GlaxoSmithKline | 8.3 |
| Randall & Quilter | 7.6 |
| Vesuvius | 6.2 |
| Redrow | 6.1 |
| Morrisons | 4.9 |
| Hornby | 4.7 |
| JD Wetherspoon | 3.8 |
| easyJet | 3.7 |
| Others (5) | 11.8 |
| Cash Position | 3.4 |

Trust Performance

The appointment of Phoenix Asset Management Partners ("PAMP") as Aurora's investment manager came into effect in January 2016.

The NAV was down 1.2% and the market was down 1.9%.

Potential investors often ask us whether the investment strategy draws us to companies of a certain size or to those in particular industries. What we do is simple; we invest in high quality businesses whose shares are selling for a "value" price. Provided we understand the nature of their business (no trifling matter – we reject many potential investments because we can't figure them out) and if our research is correct, we think this strategy will deliver favourable long-term investment returns, regardless of the size of the business or the industry they are in. Our two recent investments, in Hornby and GSK, are examples of how broad the church can be!

As mentioned in last month's factsheet, we recently added 3% to the holding in GSK, taking it to a 8.3% portfolio weight. We paid less than £13 for shares that we think are worth approximately twice that. The history of the pharmaceutical industry is one of a perpetual cycle of research, drug discovery and patent expiry. Although the world's great pharma' businesses tend to endure, "blockbuster" products rarely do. Yet, today's largest pharma firms were equally dominant during much of the 20th century. Why? Because they are highly effective and resilient industrial enterprises, with innovation, scale and distribution capabilities that are difficult to usurp. GSK continues to reshape itself, as a suite of new pharmaceutical products replaces those of the past. Furthermore, the Consumer Healthcare division has similar characteristics to a branded FMCG business and serves a market with great long-term demographics with consumers who are increasingly willing to use the internet to educate themselves and self-medicate. The vaccine's business has unusual, significant, and sustainable barriers to entry and therefore pricing power; a sign of a great business.

Also mentioned last month, we recently added 4% to the Hornby investment, whose weight in the portfolio is now 4.7%. As we have said before, Hornby owns a portfolio of heritage hobby brands in the model rail and car market. These strong brands, including Corgi, Hornby and Airfix, have not achieved their full potential over recent years, following a series of operational and manufacturing setbacks. Towards the end of 2017, Phoenix had the opportunity to substantially increase its investment in Hornby in exchange for a controlling stake, part of which is held by Aurora. We made the recent investment because, despite the challenges Hornby faces and despite recent disappointing news, the current management team are making positive changes that should help the business in the long-term and therefore underpin the investment case.

NOTE: Client accounts managed by Phoenix Asset Management Partners, including Aurora, own 75% of Hornby's issued share capital.




Aurora Track Record

| Performance | NAV Return % | Share Price Return % ** | All-Share Index % ** | Relative NAV to ASX % |
|-------------------|--------------|-------------------------|----------------------|-----------------------|
| 2018 (31 January) | -1.2 | 0.0 | -1.9 | 0.7 |
| 2017 | 20.4* | 21.2* | 13.1 | 6.5 |
| 2016 | 6.6* | 12.0 | 16.8 | -5.2 |
| 2015 | -2.3 | 4.3 | 0.9 | -3.2 |
| 2014 | -11.3 | -10.6 | 1.2 | -12.5 |
| 2013 | 3.6 | 14.2 | 20.8 | -17.2 |
| 2012 | -3.8 | -3.9 | 12.5 | -16.3 |

*Following an internal review these figures were amended in June 2018.

** Share price return with dividends reinvested; All Share Index returns with dividends reinvested.

Aurora Share Price & NAV per Share – 31 January 2018



Aurora shares are eligible to be invested in an ISA. Neither the Aurora Investment Trust nor Phoenix Asset Management Partners run such a scheme. You should consult a financial adviser regarding a suitable self-select ISA provider.




Phoenix UK Fund Track Record

| Fund Performance (%) | Gross Return | Net Return | FTSE All-Share Index* | Relative NAV to ASX |
|-----------------------------|--------------|------------|-----------------------|---------------------|
| Cumulative Since Inception* | 964.4 | 543.8 | 183.4 | 360.4 |
| Since Inception Annualised* | 12.7 | 9.9 | 5.4 | 4.5 |

*Since May 1998

The investment strategy of the Aurora Investment Trust is the same as that of the Phoenix UK Fund.

Phoenix UK Fund Value of £1,000 invested at launch to 31 Jan 2018



* Data from 30 April 1998, All-Share Index Returns with dividends reinvested

Investment Objective

We seek to achieve long-term returns by investing in UK-listed equities using a value-based philosophy inspired by the teachings of Warren Buffett, Charlie Munger, Benjamin Graham and Phillip Fisher. Our approach, combined with thorough research, invests in high quality businesses run by honest and competent management purchased at prices that, even with low expectations, will deliver excellent returns.

Contact

[Phoenix Asset Management Partners Ltd](#)
64 – 66 Glenthams Road London SW13 9JJ
Tel: +44 (0) 208 600 0100
Fund Manager since 28 January 2016

Portfolio Manager: Gary Channon

Listing: London Stock Exchange

Inception Date: 13 March 1997

ISIN: GB0000633262

Bloomberg: ARR

Fees

Management: None

Performance: One third of returns in excess of the market

Regulatory Notice:

Aurora Investment Trust Plc ("the Trust") is a UK investment trust listed on the London Stock Exchange. Past performance is no guarantee of future performance. The value of investments and any income from them may go down as well as up and investors may not get back the amount invested. There can be no assurance that the Company's investment objective will be achieved and investment results may vary substantially over time. This document is for information purposes only and does not constitute an offer or invitation to purchase shares in the Trust. Shares in an investment trust are traded on a stock market and the share price will fluctuate in accordance with supply and demand and may not reflect the underlying net asset value of the shares. This document is issued and approved by Phoenix Asset Management Partners Limited which is authorised and regulated by the Financial Conduct Authority.